Technical Analysis for GBT - Global Blood Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
84.75 | -1.09% | -0.93 |
GBT closed up 1.77 percent on Thursday, January 16, 2020, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical GBT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | -2.81% | |
| Pocket Pivot | Bullish Swing Setup | -2.81% | |
| Slingshot Bullish | Bullish Swing Setup | -2.81% | |
| Doji - Bearish? | Reversal | -2.81% | |
| New 52 Week High | Strength | -2.81% | |
| Stochastic Reached Overbought | Strength | -2.81% | |
| Upper Bollinger Band Walk | Strength | -2.81% | |
| Outside Day | Range Expansion | -2.81% | |
| Above Upper BB | Strength | -2.81% | |
| Overbought Stochastic | Strength | -2.81% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/25/2020
- Sector: Healthcare
- Industry: Biotechnology
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
Medicine Biopharmaceutical Medical Specialties Blood Hereditary Angioedema Sickle Cell Disease Angioedema Hemoglobin Hemoglobins
Medicine Biopharmaceutical Medical Specialties Blood Hereditary Angioedema Sickle Cell Disease Angioedema Hemoglobin Hemoglobins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 87.5 |
| 52 Week Low | 43.69 |
| Average Volume | 1,302,287 |
| 200-Day Moving Average | 57.72 |
| 50-Day Moving Average | 69.79 |
| 20-Day Moving Average | 80.61 |
| 10-Day Moving Average | 82.45 |
| Average True Range | 3.43 |
| ADX | 29.8 |
| +DI | 27.24 |
| -DI | 20.49 |
| Chandelier Exit (Long, 3 ATRs ) | 77.20 |
| Chandelier Exit (Short, 3 ATRs ) | 81.90 |
| Upper Bollinger Band | 86.73 |
| Lower Bollinger Band | 74.50 |
| Percent B (%b) | 1.04 |
| BandWidth | 15.18 |
| MACD Line | 3.90 |
| MACD Signal Line | 3.95 |
| MACD Histogram | -0.0447 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 94.69 | ||||
| Resistance 3 (R3) | 93.95 | 90.73 | 93.44 | ||
| Resistance 2 (R2) | 90.73 | 88.82 | 91.09 | 93.02 | |
| Resistance 1 (R1) | 88.96 | 87.64 | 89.85 | 89.70 | 92.61 |
| Pivot Point | 85.74 | 85.74 | 86.18 | 86.10 | 85.74 |
| Support 1 (S1) | 83.97 | 83.83 | 84.86 | 84.71 | 81.79 |
| Support 2 (S2) | 80.75 | 82.65 | 81.11 | 81.38 | |
| Support 3 (S3) | 78.98 | 80.75 | 80.96 | ||
| Support 4 (S4) | 79.72 |
